HUP9904092A3 - Pharmaceutical composition for treatment hiv and cancer and process for producing it - Google Patents

Pharmaceutical composition for treatment hiv and cancer and process for producing it

Info

Publication number
HUP9904092A3
HUP9904092A3 HU9904092A HUP9904092A HUP9904092A3 HU P9904092 A3 HUP9904092 A3 HU P9904092A3 HU 9904092 A HU9904092 A HU 9904092A HU P9904092 A HUP9904092 A HU P9904092A HU P9904092 A3 HUP9904092 A3 HU P9904092A3
Authority
HU
Hungary
Prior art keywords
cancer
producing
pharmaceutical composition
treatment hiv
hiv
Prior art date
Application number
HU9904092A
Other languages
English (en)
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of HUP9904092A2 publication Critical patent/HUP9904092A2/hu
Publication of HUP9904092A3 publication Critical patent/HUP9904092A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
HU9904092A 1997-05-16 1997-11-26 Pharmaceutical composition for treatment hiv and cancer and process for producing it HUP9904092A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4672697P 1997-05-16 1997-05-16

Publications (2)

Publication Number Publication Date
HUP9904092A2 HUP9904092A2 (hu) 2000-04-28
HUP9904092A3 true HUP9904092A3 (en) 2000-07-28

Family

ID=21945046

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904092A HUP9904092A3 (en) 1997-05-16 1997-11-26 Pharmaceutical composition for treatment hiv and cancer and process for producing it

Country Status (19)

Country Link
EP (1) EP0954309A1 (hu)
JP (1) JP2000510156A (hu)
KR (1) KR20000049064A (hu)
CN (1) CN1254281A (hu)
AR (1) AR009968A1 (hu)
AU (1) AU7402998A (hu)
BR (1) BR9712981A (hu)
CA (1) CA2268848A1 (hu)
CO (1) CO5070657A1 (hu)
CZ (1) CZ124999A3 (hu)
HU (1) HUP9904092A3 (hu)
IL (1) IL129351A0 (hu)
NO (1) NO991701L (hu)
PE (1) PE11499A1 (hu)
PL (1) PL335160A1 (hu)
SK (1) SK46999A3 (hu)
TR (1) TR199901530T2 (hu)
WO (1) WO1998051303A1 (hu)
ZA (1) ZA979095B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
JP2002537327A (ja) * 1999-02-26 2002-11-05 ナプロ バイオセラピューティクス,インコーポレイテッド 前立腺癌の治療レジメ
CA2366697A1 (en) * 1999-02-26 2000-08-31 Larry Helson Treatment regimen for hormone-sensitive cancers
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
AU2001286744A1 (en) * 2000-08-25 2002-03-04 Beth Israel Deaconess Medical Center Compounds and methods for inhibiting neuronal cell death
US6407105B1 (en) * 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
EP1330441A2 (en) * 2000-09-26 2003-07-30 The University of Arizona Foundation Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections
AU2002239395A1 (en) * 2000-11-01 2002-06-03 The Procter And Gamble Company Hiv treatment with benzimidazoles
JP2004115397A (ja) * 2002-09-25 2004-04-15 Fuji Photo Film Co Ltd 血管疾患治療薬を含むリポソーム
AU2005313839B2 (en) * 2004-12-06 2010-03-11 Pitney Pharmaceuticals Pty Limited Treatment for cancer
PT1830847E (pt) 2004-12-06 2015-02-05 Pitney Pharmaceuticals Pty Ltd Tratamento para o cancro
US7727967B2 (en) * 2006-02-24 2010-06-01 Boise State University Cyanooxime inhibitors of carbonyl reductase and methods of using said inhibitors in treatments involving anthracyclines
WO2009043093A1 (en) * 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
CN101643729B (zh) * 2008-08-07 2011-12-28 复旦大学 核酸分子nrn1sr22及其在制备抗癌药物中的应用
EP3119768B1 (en) 2014-03-16 2019-07-31 Hadasit Medical Research Services And Development Ltd. 3,4-bromo or -sulfonate substituted 1h-pyrrole-2,5-dione derivatives as type iii deiodinase (dio3) inhibitors for treating depressions and cancer
CN105418711A (zh) * 2015-11-06 2016-03-23 山东大学 一种α-L-鼠李糖苷酶在制备羟基脲糖苷衍生物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9420017B (sl) * 1993-03-31 2003-12-31 Merck & Co. Inc. Inhibitorji proteaze hiv-a v farmacevtskih kombinacijah za zdravljenje aids-a
US5665713A (en) * 1995-04-12 1997-09-09 Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US5656615A (en) * 1995-04-12 1997-08-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals
TR199701151T1 (xx) * 1995-04-12 1998-03-21 The Procter & Gamble Company Vir�sler ve kanserlerin geli�mesini �nlemeye mahsus, N-klorofenil karbamatlar� ve N-klorofeniltiokarbamatlar� i�eren bir farmas�tik bile�im.
HUP9903420A3 (en) * 1995-08-04 2001-12-28 Procter & Gamble Use of fluconazole for the preparation of pharmaceutical compositions, inhibiting the growth of cancers and treating viral infections

Also Published As

Publication number Publication date
BR9712981A (pt) 2000-04-18
TR199901530T2 (xx) 1999-10-21
NO991701D0 (no) 1999-04-09
WO1998051303A1 (en) 1998-11-19
PL335160A1 (en) 2000-04-10
CN1254281A (zh) 2000-05-24
AR009968A1 (es) 2000-05-17
CO5070657A1 (es) 2001-08-28
ZA979095B (en) 1998-05-11
EP0954309A1 (en) 1999-11-10
PE11499A1 (es) 1999-03-01
CZ124999A3 (cs) 1999-09-15
AU7402998A (en) 1998-12-08
JP2000510156A (ja) 2000-08-08
IL129351A0 (en) 2000-02-17
NO991701L (no) 2000-01-17
HUP9904092A2 (hu) 2000-04-28
CA2268848A1 (en) 1998-11-19
SK46999A3 (en) 2000-05-16
KR20000049064A (ko) 2000-07-25

Similar Documents

Publication Publication Date Title
HUP9904092A3 (en) Pharmaceutical composition for treatment hiv and cancer and process for producing it
HU9603484D0 (en) Pharmaceutical compositions and process for producing symptom-transduction
IL117957A0 (en) Pharmaceutical compositions for the treatment of impotence
IL112969A0 (en) Pharmaceutical composition comprising t-cell actiVator for the treatment of cancer
IL131298A0 (en) A pharmaceutical composition and a process for producing the same
HUP0003608A3 (en) Tetrahydroisoquinoline derivatives, process for producing them and pharmaceutical compositions containing them
HU9800781D0 (en) Propanolamine derivatives, process for producing them, pharmaceutical compositions containing them and their use
HUP0001522A3 (en) Benzoimidazole derivatives, process for producing them and pharmaceutical compositions containing them
HUP9700598A3 (en) Process for producing pharmaceutical composition useful for profilacting and treating pancreatitis
HU9802180D0 (en) Process for producing pharmaceutical compositions
AU3142400A (en) A pharmaceutical composition for treating angiocardiopathy and the method of producing thereof
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
HUP0003823A3 (en) Cyanoguanidines process for producing them and pharmaceutical compositions containing them
HUP0101256A3 (en) Pharmaceutical composition having antitumor activity and process for the preparation thereof
IL121329A0 (en) A pharmaceutical composition for the treatment of cancer
HUP9601331A3 (en) Piperazine- and homopiperazine-derivatives, process for producing them and pharmaceutical compositions containing them
HUP0003766A3 (en) Isoguinolin derivatives, process for producing them and pharmaceutical compositions containing them
HUP0003566A3 (en) Process for producing dosage form and the obtained product
HUP0003997A3 (en) 3-benzylpiperidine derivatives, pharmaceutical compositions containing them and process for producing them
HUP9902559D0 (en) Pharmaceutical composition and process for producing it
HU9603364D0 (en) Pharmaceutical composition and process for producing it
HUP0003236A3 (en) Medicinal compositions for treating immunodeficiency diseases
HU9802515D0 (en) Pharmaceutical compositions for treating allergias and process for producing former compositions
HU9700608D0 (en) Transdermal pharmaceutical compositions containing selegiline, and process for producing them
HU9601450D0 (en) Process for producing pharmaceutical composition for treating neoplasmic syndromas